More on Hwang Woo-Suk

Ian Wilmut is prepared to tread in the area of Hwang Woo-Suk's fraud, so-called therapeutic cloning (SCNT of humans to generate "patient specific" stem cell lines). Ian Wilmut stated: "There may be something fundamentally different about the biology of primates." Wilmut believes the controversial human research should be expedited, rather than attempting to perfect the technique in animals first, as opponents of therapeutic cloning argue.

IPBiz notes that Wilmut's arguments seriously undercut the arguments of PubPat and FTCR as to the "obviousness" of the Thomson / WARF patents on human stem cells. If there is something fundamentally different about primates, then work on mice does not render human work obvious.

****
Yonhap News reported on November 23: South Korea's blue-ribbon panel on research ethics said Thursday [Nov. 23] it is considering limiting the number of ova women can donate in her lifetime for research purposes.

The move was contained in a final report by the National Bioethics Committee (NBC) on the scandal surrounding disgraced scientist Hwang Woo-suk's past stem cell studies, which had serious ethical lapses.

It's not clear that California's CIRM has considered such a proposal.